David Neal publications

Prostate Cancer Metabolite Quantification Relative To Water In H-1-MRSI In Vivo At 3 Tesla
McLean MA;Barrett T;Gnanapragasam VJ;Priest AN;Joubert I;Lomas DJ;Neal DE;Griffiths JR;Sala E
Magn Reson Med 2011; 65 (4 ):914-919.
PubMed;  DOI: 10.1002/mrm.22703.

Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels
Gudmundsson J;Besenbacher S;Sulem P;Gudbjartsson DF;Olafsson I;Arinbjarnarson S;Agnarsson BA;Benediktsdottir KR;Isaksson HJ;Kostic JP;Gudjonsson SA;Stacey SN;Gylfason A;Sigurdsson A;Holm H;Bjornsdottir US;Eyjolfsson GI;Navarrete S;Fuertes F;Garcia-Prats MD;Polo E;Checherita IA;Jinga M;Badea P;Aben KK;Schalken JA;van Oort IM;Sweep FC;Helfand BT;Davis M;Donovan JL;Hamdy FC;Kristjansson K;Gulcher JR;Masson G;Kong A;Catalona WJ;Mayordomo JI;Geirsson G;Einarsson GV;Barkardottir RB;Jonsson E;Jinga V;Mates D;Kiemeney LA;Neal DE;Thorsteinsdottir U;Rafnar T;Stefansson K
Sci Transl Med 2010; 2 (62 ):62ra92.
PubMed;  DOI: 10.1126/scitranslmed.3001513.

RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?
Whitaker HC;Neal DE
Curr Cancer Drug Targets 2010; 10 (8):834-839.
PubMed; 

The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine
Whitaker HC;Kote-Jarai Z;Ross-Adams H;Warren AY;Burge J;George A;Bancroft E;Jhavar S;Leongamornlert D;Tymrakiewicz M;Saunders E;Page E;Mitra A;Mitchell G;Lindeman GJ;Evans DG;Blanco I;Mercer C;Rubinstein WS;Clowes V;Douglas F;Hodgson S;Walker L;Donaldson A;Izatt L;Dorkins H;Male A;Tucker K;Stapleton A;Lam J;Kirk J;Lilja H;Easton D;Cooper C;Eeles R;Neal DE;IMPACT Study Steering Comm;IMPACT Study Collaborators;UK GPCS Collaborators
PLoS ONE 2010; 5 (10):e13363.
UKPubMed (open access);  PubMed;  DOI: 10.1371/journal.pone.0013363.

Thiol isomerases negatively regulate the cellular shedding activity of ADAM17
Willems SH;Tape CJ;Stanley PL;Taylor NA;Mills IG;Neal DE;McCafferty J;Murphy G
Biochem J 2010; 428 (Pt 3):439-450.
PubMed;  DOI: 10.1042/BJ20100179.

The Potential Value of Microseminoprotein-beta as a Prostate Cancer Biomarker and Therapeutic Target
Whitaker HC;Warren AY;Eeles R;Kote-Jarai Z;Neal DE
Prostate 2010; 70 (3):333-340.
PubMed;  DOI: 10.1002/pros.21059.

Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer
Ross-Innes CS;Stark R;Holmes KA;Schmidt D;Spyrou C;Russell R;Massie CE;Vowler SL;Eldridge M;Carroll JS
Genes Dev 2010; 24 (2):171-182.
UKPubMed (open access);  PubMed;  DOI: 10.1101/gad.552910.

Nuclear trafficking and functions of endocytic proteins implicated in oncogenesis.
Borlido J;Zecchini V;Mills IG
Traffic 2009; 10 (9):1209-1220.
PubMed;  DOI: 10.1111/j.1600-0854.2009.00922.x.

Screening for prostate cancer remains controversial
Neal DE;Donovan JL;Martin RM;Hamdy FC
Lancet 2009; 374 (9700):1482-1483.
PubMed;  DOI: 10.1016/S0140-6736(09)61085-0.

Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression
Thirkettle HJ;Mills IG;Whitaker HC;Neal DE
Oncogene 2009; 28 (41):3663-3670.
PubMed;  DOI: 10.1038/onc.2009.223.

Stage shift in PSA-detected prostate cancers - effect modification by Gleason score
Pashayan N;Pharoah P;Neal DE;Hamdy F;Donovan J;Martin RM;Greenberg D;Duffy SW
J Med Screen 2009; 16 (2):98-101.
UKPubMed (open access);  PubMed;  DOI: 10.1258/jms.2009.009037.

Chromatin immunoprecipitation (ChIP) methodology and readouts.
Massie CE;Mills IG
Methods Mol Biol 2009; 505 ():123-137.
PubMed;  DOI: 10.1007/978-1-60327-575-0_7.

Cancer, Chemistry, and the Cell: Molecules that Interact with the Neurotensin Receptors
Myers RM;Shearman JW;Kitching MO;Ramos-Montoya A;Neal DE;Ley SV
ACS Chem Biol 2009; 4 (7):503-525.
PubMed;  DOI: 10.1021/cb900038e.

LYRIC/AEG-1 Is Targeted to Different Subcellular Compartments by Ubiquitinylation and Intrinsic Nuclear Localization Signals
Thirkettle HJ;Girling J;Warren AY;Mills IG;Sahadevan K;Leung H;Hamdy F;Whitaker HC;Neal DE
Clin Cancer Res 2009; 15 (9):3003-3013.
PubMed;  DOI: 10.1158/1078-0432.CCR-08-2046.

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening
Pashayan N;Duffy SW;Pharoah P;Greenberg D;Donovan J;Martin RM;Hamdy F;Neal DE
Br J Cancer 2009; 100 (7):1198-1204.
UKPubMed (open access);  PubMed;  DOI: 10.1038/sj.bjc.6604973.

Identification of new genetic risk factors for prostate cancer
Guy M;Kote-Jarai Z;Giles GG;Al Olama AA;Jugurnauth SK;Mulholland S;Leongamornlert DA;Edwards SM;Morrison J;Field HI;Southey MC;Severi G;Donovan JL;Hamdy FC;Dearnaley DP;Muir KR;Smith C;Bagnato M;Ardern-Jones AT;Hall AL;O'Brien LT;Gehr-Swain BN;Wilkinson RA;Cox A;Lewis S;Brown PM;Jhavar SG;Tymrakiewicz M;Lophatananon A;Bryant SL;Horwich A;Huddart RA;Khoo VS;Parker CC;Woodhouse CJ;Thompson A;Christmas T;Ogden C;Fisher C;Jameson C;Cooper CS;English DR;Hopper JL;Neal DE;Easton DF;Eeles RA;UK Genetic Prostate Canc Study;British Assoc Urological Surg
Asian J Androl 2009; 11 (1):49-55.
PubMed;  DOI: 10.1038/aja.2008.18.

A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer
Kote-Jarai Z;Jugurnauth S;Mulholland S;Leongamornlert DA;Guy M;Edwards S;Tymrakiewitcz M;O'Brien L;Hall A;Wilkinson R;Al Olama AA;Morrison J;Muir K;Neal D;Donovan J;Hamdy F;Easton DF;Eeles R;UKGPCS Collaborators;British Assoc Urological Surg Sect
Br J Cancer 2009; 100 (2):426-430.
UKPubMed (open access);  PubMed;  DOI: 10.1038/sj.bjc.6604847.

Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified
Down L;Metcalfe C;Avery K;Noble S;Lane JA;Neal DE;Hamdy FC;Donovan JL
J Clin Epidemiol 2009; 62 (1):67-73.

Development of a complex intervention improved randomization and informed consent in a randomized controlled trial
Donovan JL;Lane JA;Peters TJ;Brindle L;Salter E;Gillatt D;Powell P;Bollina P;Neal DE;Hamdy FC;ProtecT Study Grp
J Clin Epidemiol 2009; 62 (1):29-36.

Pro-neural transcription factors as cancer markers
Vias M;Massie CE;East P;Scott H;Warren A;Zhou ZX;Nikitin AY;Neal DE;Mills IG
BMC Med Genomics 2008; 1 ():17.
PubMed;  DOI: 10.1186/1755-8794-1-17.

Terminal and progenitor lineage-survival oncogenes as cancer markers
Vias M;Ramos-Montoya A;Mills IG
Trends Mol Med 2008; 14 (11):486-494.
PubMed;  DOI: 10.1016/j.molmed.2008.09.002.

ChIPping away at gene regulation
Massie CE;Mills IG
EMBO Rep 2008; 9 (4):337-343.
UKPubMed (open access);  PubMed;  DOI: 10.1038/embor.2008.44.

Clathrin is spindle-associated but not essential for mitosis
Borlido J;Veltri G;Jackson AP;Mills IG
PLoS ONE 2008; 3 (9):e3115.
UKPubMed (open access);  PubMed;  DOI: 10.1371/journal.pone.0003115.

Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
Avery KNL;Metcalfe C;Blazeby JM;Lane JA;Neal DE;Hamdy FC;Donovan JL
BJU Int 2008; 102 (11):1629-1633.
PubMed;  DOI: 10.1111/j.1464-410X.2008.07879.x.

AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma
Veerakumarasivam A;Goldstein LD;Saeb-Parsy K;Scott HE;Warren A;Thorne NP;Mills IG;Venkitaraman A;Neal DE;Kelly JD
Cell Cycle 2008; 7 (22):3525-3533.

Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study
Collin SM;Metcalfe C;Donovan J;Lane JA;Davis M;Neal D;Hamdy F;Martin RM
BJU Int 2008; 102 (10):1400-1406.

Can we accurately identify men with low risk prostate cancer?
Neal DE
J Urol 2008; 180 (4 Pt 1):1217-1218.

Variation in KLK genes, prostate-specific antigen and risk of prostate cancer - Reply
Eeles R;Giles G;Neal D;Muir K;Easton DF;PRACTICAL Consortium
Nat Genet 2008; 40 (9):1035-1036.

Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL consortium
Kote-Jarai Z;Easton DF;Stanford JL;Ostrander EA;Schleutker J;Ingles SA;Schaid D;Thibodeau S;Dork T;Neal D;Cox A;Maier C;Vogel W;Guy M;Muir K;Lophatananon A;Kedda MA;Spurdle A;Steginga S;John EM;Giles G;Hopper J;Chappuis PO;Hutter P;Foulkes WD;Hamel N;Salinas CA;Koopmeiners JS;Karyadi DM;Johanneson B;Wahlfors T;Tammela TL;Stern MC;Corral R;McDonnell SK;Schurmann P;Meyer A;Kuefer R;Leongamornlert DA;Tymrakiewicz M;Liu JF;O'Mara T;Gardiner RA;Aitken J;Joshi AD;Severi G;English DR;Southey M;Edwards SM;Al Olama AA;Eeles RA;PRACTICAL Consortium
Cancer Epidemiol Biomarkers Prev 2008; 17 (8):2052-2061.
UKPubMed (open access);  PubMed;  DOI: 10.1158/1055-9965.EPI-08-0317.

MT1-MMP regulates urothelial cell invasion via transcriptional regulation of Dickkopf-3
Saeb-Parsy K;Veerakumarasivam A;Wallard MJ;Thorne N;Kawano Y;Murphy G;Neal DE;Mills IG;Kelly JD
Br J Cancer 2008; 99 (4):663-669.
UKPubMed (open access);  PubMed;  DOI: 10.1038/sj.bjc.6604513.

Alterations in beta-catenin expression and localization in prostate cancer
Whitaker HC;Girling J;Warren AY;Leung H;Mills IG;Neal DE
Prostate 2008; 68 (11):1196-1205.
PubMed;  DOI: 10.1002/pros.20780.

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
Attard G;Clark J;Ambroisine L;Mills IG;Fisher G;Flohr P;Reid A;Edwards S;Kovacs G;Berney D;Foster C;Massie CE;Fletcher A;De Bono JS;Scardino P;Cuzick J;Cooper CS;Transatlantic Prostate Grp
Br J Cancer 2008; 99 (2):314-320.
UKPubMed (open access);  PubMed;  DOI: 10.1038/sj.bjc.6604472.

Multiple loci with different cancer specificities within the 8q24 gene desert
Ghoussaini M;Song HL;Koessler T;Al Olama AA;Kote-Jarai Z;Driver KE;Pooley KA;Ramus SJ;Kjaer SK;Hogdall E;DiCioccio RA;Whittemore AS;Gayther SA;Giles GG;Guy M;Edwards SM;Morrison J;Donovan JL;Hamdy FC;Dearnaley DP;Ardern-Jones AT;Hall AL;O'Brien LT;Gehr-Swain BN;Wilkinson RA;Brown PM;Hopper JL;Neal DE;Pharoah PDP;Ponder BAJ;Eeles RA;Easton DF;Dunning AM;UK Genetic Prostate Canc Study Col;UK ProtecT Study Collaborators
J Natl Cancer Inst 2008; 100 (13):962-966.
PubMed;  DOI: 10.1093/jnci/djn190.

Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study
Collin SM;Martin RM;Metcalfe C;Gunnell D;CAlbertsen P;Neal D;Hamdy F;Stephens P;Lane JA;Moore R;Donovan J
Lancet Oncol 2008; 9 (5):445-452.
UKPubMed (open access);  PubMed;  DOI: 10.1016/S1470-2045(08)70104-9.

High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53
Veerakumarasivam A;Scott HE;Chin SF;Warren A;Wallard MJ;Grimmer D;Ichimura K;Caldas C;Collins VP;Neal DE;Kelly JD
Clin Cancer Res 2008; 14 (9):2527-2534.

Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer
Aitchison AA;Veerakumarasivam A;Vias M;Kumar R;Hamdy FC;Neal DE;Milis IG
Prostate 2008; 68 (6):661-674.
PubMed;  DOI: 10.1002/pros.20730.

Structural basis for the nuclear import of the human androgen receptor
Cutress ML;Whitaker HC;Mills IG;Stewart M;Neal DE
J Cell Sci 2008; 121 (7):957-968.
PubMed;  DOI: 10.1242/jcs.022103.

Multiple newly identified loci associated with prostate cancer susceptibility
Eeles RA;Kote-Jarai Z;Giles GG;Al Olama AA;Guy M;Jugurnauth SK;Mulholland S;Leongamornlert DA;Edwards SM;Morrison J;Field HI;Southey MC;Severi G;Donovan JL;Hamdy FC;Dearnaley DP;Muir KR;Smith C;Bagnato M;Ardern-Jones AT;Hall AL;O'Brien LT;Gehr-Swain BN;Wilkinson RA;Cox A;Lewis S;Brown PM;Jhavar SG;Tymrakiewicz M;Lophatananon A;Bryant SL;Horwich A;Huddart RA;Khoo VS;Parker CC;Woodhouse CJ;Thompson A;Christmas T;Ogden C;Fisher C;Jamieson C;Cooper CS;English DR;Hopper JL;Neal DE;Easton DF;Uk Genetic Prostate Canc Study Col;British Assoc Urological Surg Sect;Uk ProtecT Study Collaborators
Nat Genet 2008; 40 (3):316-321.

Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004
Hussain S;Gunnell D;Donovan J;McPhail S;Hamdy F;Neal D;Albertsen P;Verne J;Stephens P;Trotter C;Martin RM
BJU Int 2008; 101 (5):547-555.
UKPubMed (open access);  PubMed;  DOI: 10.1111/j.1464-410X.2007.07338.x.

Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group
Metcalfe C;Martin RM;Noble S;Lane JA;Hamdy FC;Neal DE;Donovan JL
J Med Ethics 2008; 34 (1):37-40.
UKPubMed (open access);  PubMed;  DOI: 10.1136/jme.2006.019661.

The interplay between clathrin-coated vesicles and cell signallinge
Mills IG
Semin Cell Dev Biol 2007; 18 (4):459-470.

New androgen receptor genomic targets show an interaction with the ETS1 transcription factor
Massie CE;Adryan B;Barbosa-Morais NL;Lynch AG;Tran MG;Neal DE;Mills IG
EMBO Rep 2007; 8 (9):871-878.

Labeling and identification of LNCaP cell surface proteins: A pilot study
Whitaker HC;Stanbury DPB;Brinham C;Girling J;Hanrahan S;Totty N;Neal DE
Prostate 2007; 67 (9):943-954.

RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues
Aitchison A;Warren A;Neal D;Rabbitts P
Prostate 2007; 67 (6):638-644.

Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer
Dudderidge TJ;McCracken SR;Loddo M;Fanshawe TR;Kelly JD;Neal DE;Leung HY;Williams GH;Stoeber K
Br J Cancer 2007; 96 (9):1384-1393.

A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH
Wicker N;Carles A;Mills IG;Wolf M;Veerakumarasivam A;Edgren H;Boileau F;Wasylyk B;Schalken JA;Neal DE;Kallioniemi O;Poch O
BMC Genomics 2007; 8 ():84.

Missing channels in two-colour microarray experiments: Combining single-channel and two-channel data
Lynch AG;Neal DE;Kelly JD;Burtt GJ;Thorne NP
BMC Bioinformatics 2007; 8 ():26.

A role for neurotensin in bicalutamide resistant prostate cancer cells
Vias M;Burtt G;Culig Z;Veerakumarasivam A;Neal DE;Mills IG
Prostate 2007; 67 (2):190-202.

The developing role of receptors and adaptors
Massie C;Mills IG
Nat Rev Cancer 2006; 6 (5):403-409.

Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma
Wallard MJ;Pennington CJ;Veerakumarasivam A;Burtt G;Mills IG;Warren A;Leung HY;Murphy G;Edwards DR;Neal DE;Kelly JD
Br J Cancer 2006; 94 (4):569-577.

Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors
Mills IG;Gaughan L;Robson C;Ross T;McCracken S;Kelly J;Neal DE
J Cell Biol 2005; 170 (2):191-200.

Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation
Gaughan L;Logan IR;Neal DE;Robson CN
Nucleic Acids Res 2005; 33 (1):13-26.

Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer
Dominguez-Escrig JL;Kelly JD;Neal DE;King SM;Davies BR
Clin Cancer Res 2004; 10 (14):4874-4884.

Upregulation and nuclear recruitment of HDACI in hormone refractory prostate cancer
Halkidou K;Gaughan L;Cook S;Leung HY;Neal DE;Robson CN
Prostate 2004; 59 (2):177-189.

Putative involvement of the histone acetyltransferase Tip60 in ribosomal gene transcription
Halkidou K;Logan IR;Cook S;Neal DE;Robson CN
Nucleic Acids Res 2004; 32 (5):1654-1665.

Control of human PIRH2 protein stability - Involvement of TIP60 and the proteasome
Logan IR;Sapountzi V;Gaughan L;Neal DE;Robson CN
J Biol Chem 2004; 279 (12):11696-11704.

Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate
Halkidou K;Cook S;Leung HY;Neal DE;Robson CN
Eur Urol 2004; 45 (3):382-389.

Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening
Oliver SE;Holly J;Peters TJ;Donovan J;Persad R;Gillatt D;Pearce A;Hamdy FC;Neal DE;Gunnell D
Urology 2004; 64 (2):317-322.

Screen-detected prostate cancer and the insulin-like growth factor axis: Results of a population-based case-control study
Oliver SE;Gunnell D;Donovan J;Peters TJ;Persad R;Gillatt D;Pearce A;Neal DE;Hamdy FC;Holly J
Int J Cancer 2004; 108 (6):887-892.

Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer
Oliver SE;Barrass B;Gunnell DJ;Donovan JL;Peters TJ;Persad RA;Gillatt D;Neal DE;Hamdy FC;Holly JMP
Cancer Epidemiol Biomarkers Prev 2004; 13 (1):163-165.

Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease?
Gunnell D;Oliver SE;Donovan JL;Peters TJ;Gillatt D;Persad R;Hamdy FC;Neal DE;Holly JMP
J Clin Endocrinol Metab 2004; 89 (1):213-218.

The scaffolding protein RACK1 interacts with androgen receptor and promotes cross-talk through a protein kinase C signaling pathway
Rigas AC;Ozanne DM;Neal DE;Robson CN
J Biol Chem 2003; 278 (46):46087-46093.

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study)
Donovan JL;Peters TJ;Noble S;Powell P;Gillatt D;Oliver SE;Lane JA;Neal DE;Hamdy FC;ProtecT Study Grp
J Clin Epidemiol 2003; 56 (7):605-609.

Ethics of clinical trials from bayesian perspective - Randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer
Hamdy FC;Donovan JL;Lane JA;Neal DE
BMJ 2003; 326 (7404):1456-1456.

Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study
Mills N;Donovan JL;Smith M;Jacoby A;Neal DE;Hamdy FC
Control Clin Trials 2003; 24 (3):272-282.

Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men
Gunnell D;Oliver SE;Peters TJ;Donovan JL;Persad R;Maynard M;Gillatt D;Pearce A;Hamdy FC;Neal DE;Holly JMP
Br J Cancer 2003; 88 (11):1682-1686.

Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development
Halkidou K;Gnanapragasam VJ;Mehta PB;Logan IR;Brady ME;Cook S;Leung HY;Neal DE;Robson CN
Oncogene 2003; 22 (16):2466-2477.

Recommendations for urological cancers issued by NICE
Neal D
Clin Oncol (R Coll Radiol) 2003; 15 (2):57-58.

MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion
Mehta PB;Jenkins BL;McCarthy L;Thilak L;Robson CN;Neal DE;Leung HY
Oncogene 2003; 22 (9):1381-1389.